GGrantIndex
← Leaderboards

Jashvant D Unadkat

University Of Washington

Google Scholar ↗PubMed ↗ORCID ↗
$14,909,800
Attributed
$17,500,436
Total exposure
21
Grants
13
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.7M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$35,560,109 · 23

By mechanism

P01$19,077,185 · 8
P50$5,621,794 · 2
R01$4,852,439 · 2
UC2$2,755,586 · 1
RC1$999,807 · 1
R33$950,362 · 1

Top collaborators

Most similar at University Of Washington

Same institution · by research overlap

Others in their field

Top investigators on “Pregnancy”

Research focus

PregnancyPharmaceutical PreparationsDosePlasmaFundingPregnant WomenPharmacologyIn VitroDrug Of AbuseReportingIn VivoClinical ResearchFetalExposure ToAffectBaseInfectionTissuesProgramsFetusToxic EffectModels And SimulationPlacentaAnimals

Grant awards (76)

Identification, Quantification, and Functional Characterization of Transporters in Human Placenta, Developing Gut and Fetal Brain$921,621
UC2 · FY2025 · HD
Identification, Quantification, and Functional Characterization of Transporters in Human Placenta, Developing Gut and Fetal Brain$912,344
UC2 · FY2024 · HD
A Systems Pharmacology approach to predict the effects of pregnancy and infectious diseases on transporter-mediated drug disposition$555,944
R01 · FY2024 · HD · contact PI
Pharmacology of Drugs of Abuse During Pregnancy$1,539,877
P01 · FY2023 · DA · contact PI
Identification, Quantification, and Functional Characterization of Transporters in Human Placenta, Developing Gut and Fetal Brain$921,621
UC2 · FY2023 · HD
A Systems Pharmacology approach to predict the effects of pregnancy and infectious diseases on transporter-mediated drug disposition$553,686
R01 · FY2023 · HD · contact PI
PBPK prediction and verification of maternal-fetal exposure to cannabinoids$515,292
P01 · FY2023 · DA · contact PI
Administrative Core$136,754
P01 · FY2023 · DA · contact PI
Pharmacology of Drugs of Abuse During Pregnancy$1,475,139
P01 · FY2022 · DA · contact PI
PBPK prediction and verification of maternal-fetal exposure to cannabinoids$478,677
P01 · FY2022 · DA · contact PI
A Systems Pharmacology approach to predict the effects of pregnancy and infectious diseases on transporter-mediated drug disposition$435,877
R01 · FY2022 · HD · contact PI
Administrative Core$132,174
P01 · FY2022 · DA · contact PI
A Systems Pharmacology approach to predict the effects of pregnancy and infectious diseases on transporter-mediated drug disposition$121,508
R01 · FY2022 · HD · contact PI
Pharmacology of Drugs of Abuse During Pregnancy$1,566,926
P01 · FY2021 · DA · contact PI
PBPK prediction and verification of maternal-fetal exposure to cannabinoids$523,374
P01 · FY2021 · DA · contact PI
A Systems Pharmacology approach to predict the effects of pregnancy and infectious diseases on transporter-mediated drug disposition$429,657
R01 · FY2021 · HD · contact PI
Administrative Core$130,578
P01 · FY2021 · DA · contact PI
Pharmacology of Drugs of Abuse During Pregnancy$1,750,186
P01 · FY2020 · DA · contact PI
PBPK prediction and verification of maternal-fetal exposure to cannabinoids$587,062
P01 · FY2020 · DA · contact PI
Administrative Core$88,845
P01 · FY2020 · DA · contact PI
Pharmacology of Drugs of Abuse During Pregnancy$1,250,017
P01 · FY2019 · DA · contact PI
PBPK prediction and verification of maternal-fetal exposure to cannabinoids$334,421
P01 · FY2019 · DA · contact PI
Administrative Core$88,845
P01 · FY2019 · DA · contact PI
Mechanisms of Drug Disposition During Pregnancy$998,989
P01 · FY2017 · DA · contact PI
Mechanisms of CYP3A induction during pergnancy$414,250
P01 · FY2017 · DA · contact PI
Administrative Core$90,634
P01 · FY2017 · DA · contact PI
Mechanisms of Drug Disposition During Pregnancy$5,767
P01 · FY2017 · DA · contact PI
Mechanisms of Drug Disposition During Pregnancy$1,002,913
P01 · FY2016 · DA · contact PI
Mechanisms of CYP3A induction during pergnancy$372,001
P01 · FY2016 · DA · contact PI
Administrative Core$77,702
P01 · FY2016 · DA · contact PI
Mechanisms of Drug Disposition During Pregnancy$9,009
P01 · FY2016 · DA · contact PI
Mechanisms of Drug Disposition During Pregnancy$1,012,455
P01 · FY2015 · DA · contact PI
Mechanisms of CYP3A induction during pergnancy$329,732
P01 · FY2015 · DA · contact PI
Administrative Core$77,533
P01 · FY2015 · DA · contact PI
Mechanisms of Drug Disposition During Pregnancy$997,675
P01 · FY2014 · DA · contact PI
Mechanisms of CYP3A induction during pergnancy$354,353
P01 · FY2014 · DA · contact PI
Administrative Core$82,854
P01 · FY2014 · DA · contact PI
Mechanisms of Drug Disposition During Pregnancy$828,926
P01 · FY2013 · DA · contact PI
Mechanisms of CYP3A induction during pergnancy$280,820
P01 · FY2013 · DA · contact PI
Administrative Core$82,258
P01 · FY2013 · DA · contact PI
Drug Interactions at the Human Blood-Brain Barrier$499,842
RC1 · FY2010 · NS · contact PI
P-glycoprotein and Alzheimer's Disease$319,693
R33 · FY2010 · AG · contact PI
Drug Interactions at the Human Blood-Brain Barrier$499,965
RC1 · FY2009 · NS · contact PI
P-glycoprotein and Alzheimer's Disease$313,512
R33 · FY2009 · AG · contact PI
Nucleoside Transporters: disposition of nucleoside drugs$366,635
R01 · FY2008 · GM · contact PI
P-glycoprotein and Alzheimer's Disease$317,157
R33 · FY2008 · AG · contact PI
MECHANISMS OF INDUCTIVE DRUG INTERACTIONS WITH ANTI-HIV PROTEASE INHIBITORS$393,817
P01 · FY2007 · GM · contact PI
Nucleoside Transporters: disposition of nucleoside drugs$366,669
R01 · FY2007 · GM · contact PI
Mechanisms By Which Maternal And Fetal Drug Exposure Is*$1,162,448
P50 · FY2006 · HD · contact PI
Nucleoside Transporters: disposition of nucleoside drugs$366,708
R01 · FY2006 · GM · contact PI
MECHANISMS OF INDUCTIVE DRUG INTERACTIONS WITH ANTI-HIV PROTEASE INHIBITORS$262,907
P01 · FY2006 · GM · contact PI
INDUCTIVE EFFECTS OF NELFINAVIR AND RITONAVIR (I)$138,560
M01 · FY2006 · RR · contact PI
DEVELOPMENTAL EXPRESSION OF P-GLYCOPROTEIN IN THE PLACENTA, FETUS AND NEONATE$94,326
P51 · FY2006 · RR · contact PI
Mechanisms By Which Maternal And Fetal Drug Exposure Is*$1,130,450
P50 · FY2005 · HD
Nucleoside Transporters: disposition of nucleoside drugs$384,547
R01 · FY2005 · GM
MECHANISMS OF INDUCTIVE DRUG INTERACTIONS WITH ANTI-HIV PROTEASE INHIBITORS$255,308
P01 · FY2005 · GM
PHARMACOKINETIC INTERACTION BETWEEN DIGOXIN AND MIDAZOLAM$216,446
M01 · FY2005 · RR
HEPATIC &INTESTINAL P-GLYCOPROT CYP3A4/5 EXPRESSION &ACTIVITY$102,588
P51 · FY2005 · RR
Mechanisms By Which Maternal And Fetal Drug Exposure Is*$1,099,385
P50 · FY2004 · HD
MECHANISMS OF INDUCTIVE DRUG INTERACTIONS WITH ANTI-HIV PROTEASE INHIBITORS$247,930
P01 · FY2004 · GM
PK INTERACTION BETWEEN DIGOXIN AND MIDAZOLAM$16,482
M01 · FY2004 · RR
Mechanisms By Which Maternal And Fetal Drug Exposure Is*$1,123,222
P50 · FY2003 · HD
UPTAKE OF NUCLEOSIDES &NUCLEOSIDE DRUGS IN INTESTINE$325,415
R01 · FY2003 · GM
MECHANISMS OF INDUCTIVE DRUG INTERACTIONS WITH ANTI-HIV PROTEASE INHIBITORS$301,185
P01 · FY2003 · GM
Enhance Effectiveness of Anti-HIV Drugs in the CNS$151,600
R21 · FY2003 · MH
STUDY OF THE FEASIBILITY OF VERAPAMIL AS AN IN VIVO SUBSTRATE OF P-GLYCOPROTEIN$90,834
P51 · FY2003 · RR
Maternal And Fetal Drug Exposure Alteration in Pregnancy$1,106,289
P50 · FY2002 · HD
UPTAKE OF NUCLEOSIDES &NUCLEOSIDE DRUGS IN INTESTINE$316,026
R01 · FY2002 · GM
Enhance Effectiveness of Anti-HIV Drugs in the CNS$151,600
R21 · FY2002 · MH
Hepatic/Intestinal P-glycoprotein and CYP3A in pregnancy$0
P50 · FY2002 · HD
UPTAKE OF NUCLEOSIDES &NUCLEOSIDE DRUGS IN INTESTINE$316,325
R01 · FY2001 · GM
Enhance Effectiveness of Anti-HIV Drugs in the CNS$265,883
R21 · FY2001 · MH
PHARACOKINETIC INTERACTIONS BETW ANTI HIV PROTEASE INHIB &DRUGS OF ABUSE$0
P51 · FY2001 · RR
THERAPEUTIC STRATEGIES TO PREVENT VERTICAL TRANSMISSION OF HIV 1 &SIV HYBRID$0
P51 · FY2001 · RR
UPTAKE OF NUCLEOSIDES &NUCLEOSIDE DRUGS IN INTESTINE$313,442
R01 · FY2000 · GM
PHARACOKINETIC INTERACTIONS BETW ANTI HIV PROTEASE INHIB &DRUGS OF ABUSE$74,617
P51 · FY2000 · RR